GP
BPMC

GLG Partners’s Blueprint Medicines BPMC Stock Holding History

GLG Partners’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-26,858
Closed -$573K – 463
2015
Q3 		$573K Buy
26,858
+1,271
+5% +$35.2K 0.02% 394
2015
Q2 		$678K Buy
+25,587
New +$731K 0.02% 384

Other funds holding BPMC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
RIM
RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

GLG Partners's BPMC Position: Q4 2015 in Review

GLG Partners sold out of Blueprint Medicines (BPMC) in Q4 2015, closing a stake of 26,858 shares — an estimated $573K sold.

GLG Partners first reported a position in BPMC in Q2 2015 and held it in 2 quarters. The position peaked at $678K in Q2 2015. 73 funds tracked by Wall St. Rank hold BPMC as of Q4 2015.

  • GLG Partners reported no remaining Blueprint Medicines position as of Q4 2015 after selling out during the quarter.
  • GLG Partners sold 26,858 Blueprint Medicines shares in Q4 2015, an estimated $573K.
  • GLG Partners first reported a position in Blueprint Medicines in Q2 2015 and held it in 2 quarters.
  • GLG Partners's Blueprint Medicines position peaked at $678K in Q2 2015.
  • 73 funds tracked by Wall St. Rank held Blueprint Medicines as of Q4 2015.

Based on GLG Partners's 13F filing for Q4 2015, filed 16 Feb 2016.